1396 K.Madziarskaetal.
vasculardisease:2006updateendorsedbytheNationalHeart,Lung, 19. vanDijkPC,ZwindermanAH,DekkerFWetal.Effectofgeneral
andBloodInstitute.AHA;ACC;NationalHeart,Lung,andBlood populationmortalityonthenorth-southmortalitygradientinpatients
Institute.JAmCollCardiol2006;47:2130–2139 onreplacementtherapyinEurope.KidneyInt2007;71:53–59
15. Kasiske BL, Cangro CB, Hariharan S et al. American Society of 20. YoshinoM,KuhlmannMK,KotankoPetal.Internationaldifferences
Transplantation.The evaluationof renal transplantationcandidates: in dialysis mortality reflect background general population athero-
clinicalpracticeguidelines.AmJTransplant2001;1:3–95 sclerotic cardiovascular mortality. J Am Soc Nephrol 2006; 17:
16. PrioriSG,AliotE,Blomstrom-LundqvistCetal.Taskforceonsud- 3510–3535
dencardiacdeathoftheEuropeanSocietyofCardiology.EurHeartJ 21. TakedaK,HaradaA,OkudaSetal.Suddendeathinchronicdialysis
2001;22:1374–1450 patients.NephrolDialTransplant1997;12:952–955
17. ReaTD,PearceRM,RaghunathanTEetal.Incidenceofout-of-hos- 22. RitzE,WannerC.Thechallengeofsuddendeathindialysispatients.
pitalcardiacarrest.AmJCardiol2004;93:1455–1460 ClinJAmSocNephrol2008;3:920–929
18. Herzog CA, Mangrum JM, Passman R. Sudden cardiac death and
dialysispatients.SeminDial2008;21:300–307 Receivedforpublication:13.12.09;Acceptedinrevisedform:26.8.10
NephrolDialTransplant(2011)26:1396–1401
doi:10.1093/ndt/gfq568
AdvanceAccesspublication17September2010
The increased risk of post-transplant diabetes mellitus in peritoneal
dialysis-treated kidney allograft recipients
KatarzynaMadziarska1,WaclawWeyde1,MagdalenaKrajewska1,DariuszPatrzalek2,DariuszJanczak2,
Mariusz Kusztal1, Hanna Augustyniak-Bartosik1, Przemyslaw Szyber2, Cyprian Kozyra3
and Marian Klinger1
1DepartmentofNephrologyandTransplantationMedicine,WroclawMedicalUniversity,Wroclaw,Poland,2DepartmentofVascular,
General andTransplantationSurgery,WroclawMedical University,Wroclaw,Polandand3Departmentof Statistics, Wroclaw
Universityof Economics,Wroclaw,Poland
Correspondence andoffprint requests to: Katarzyna Madziarska; E-mail: kmadziarska@wp.pl
Abstract Results.Inthestudygroup,72patients(23.4%)developed
Background. Post-transplant diabetes mellitus (PTDM) PTDM after RTx (55 HD and 17 PD patients). PTDM in-
is a common metabolic complication in kidney allograft cidence at 3, 6 and 12 months was 15.9%, 22.1% and
recipients, significantly contributing to the elevated car- 23.4%, respectively. The mean interval from transplant-
diovascular morbidity after renal transplantation and in- ation to the onset of PTDM was 3.08 ± 2.73 months. In
creased risk of chronic transplant dysfunction. The aim univariateanalysis,thefactorsassociatedwiththeelevated
of the present investigation was to evaluate the factors risk of PTDM appearance were older recipient age, posi-
influencing PTDM development. Under particular con- tive family history of diabetes, hypertensive nephropathy
sideration were the elements, existing before the trans- as end-stage renal disease cause, higher body mass index
plantation, especially the modality of dialysis treatment at transplantation, treatment by PD, and the graft from an
significance, i.e. haemodialysis (HD) versus peritoneal older donor. In multivariateverification, statistical signifi-
dialysis (PD). cance remained: older recipient age (P < 0.001), positive
Methods. Three hundred and seventy-seven consecutive family history of diabetes (P = 0.002), and treatment by
outpatients who underwent renal transplantation (RTx) in PD (P = 0.007).
our institution between January 2003 and December Conclusions. Treatment by PD appears to be a possible
2005 were analysed. PTDM was diagnosed according to novelfactor, not yetreported, whichmay increase the risk
the current American Diabetic Association/World Health of PTDM development.
Organization criteria. Statistical inference was conducted
Keywords:modalityofdialysistreatment;peritonealdialysisversus
bymeansofunivariatemethods(onefactorversusPTDM)
haemodialysis;post-transplantdiabetesmellitus;pre-transplantrisk
and multivariate methods in frames of generalized linear
factors
model.
©TheAuthor2010.PublishedbyOxfordUniversityPressonbehalfofERA-EDTA.Allrightsreserved.
ForPermissions,pleasee-mail:journals.permissions@oxfordjournals.org
Downloaded
from
http://ndt.oxfordjournals.org/
by
guest
on
November
13,
2015
TheincreasedriskofPTDMinPD-treatedkidneyrecipients 1397
Introduction Finally,thestudygroupencompassed356kidneyallograftrecipients
withgraftfunctioning>12months.Forty-eightrecipients(13.5%)were
alreadydiabeticduringdialysis.
Post-transplant diabetes mellitus (PTDM) is a common Therefore, the final analysis included 308 patients (all Caucasian)
metabolic complication in kidney allograft recipients ap- whose clinical characteristics (quantitative and qualitative parameters)
pearing in 4–30% of patients [1–4]. arepresentedinTables1and2.
Statistical analysis was performed with Statistica 8.0 software by
ItisalsowellknownthatPTDMcontributessignificant-
meansof univariate methods(one factor versusPTDM): Pearson’schi-
ly to the elevated cardiovascular morbidity after kidney
square test of independence (testing dependencies between categorical
transplantation and increased risk of chronic transplant variables), non-parametric Mann–WhitneyU-test (comparing means of
dysfunction[1,5,6].PathogenesisofPTDMembracesboth qualitativevariablesinthetwogroups,whenbinaryvariable—PDTM—
impairment of insulin secretion and peripheral resistance couldbethecauseofdifferences),andsimplelogisticregression(inves-
tigatinginfluenceofonequalitativevariableonPDTM).Multivariateana-
[7].
lysiswasconductedinframesofgeneralizedlinear model(GLM)with
In most studies, the main focus was paid to factors thelogitlinkfunction(investigatingmanyqualitativeandcategoricalvari-
affecting PTDM occurrence in the post-transplantation ablesto test their independent influence on PTDM). Statistical signifi-
period, such as the type of calcineurin inhibitor used cancewasrecognized withP-value<0.05.ResultswithP-valuegreater
thanthesignificancelevelbut<0.1arealsomentioned.Theparameters
(cyclosporineversus tacrolimus), acute rejection rate, cu-
ofquantitativevariablesaregivenasmean±SD.
mulative steroid dose, viral infection presence, number of
In thecyclosporine subgroup, the steroid administration was as fol-
HLA mismatches and quality of the transplanted organ lows: Day0—perioperativemethylprednisolone 500 mgi.v.bolus,Day
[1,8–11]. 1—250 mg i.v. bolus, Day 2—125 mg i.v. bolus, Day 3–14—40 mg
However, less attention was devoted to factors deriving prednisone p.o., Day 15–28—30 mg prednisone p.o., Day 29–42—
20 mg prednisone p.o., Day 43–60—15 mg prednisone p.o., and from from chronic dialysis treatment. Therefore, the aim of the Day 61—10 mg prednisone.
present investigation was to evaluate the factors influen- In the tacrolimus subgroup, significantly smaller steroid doses were
cingtheoccurrenceofPTDM,includingthoseexistingbe- given:Day0—perioperativemethylprednisolone500mgi.v.bolus,Day
foretransplantationinthedialysisperiod.Underparticular 1—125 mg i.v. bolus, Day 2–14—20 mg prednisone p.o., Day 15–28
—15 mg prednisone, Day 29–42—10 mg prednisone p.o., and from consideration was the modality of dialysis treatment with
Day 43—5 mg prednisone p.o.
the purpose of determination, whether being treated by
Themeanyearlycumulativeprednisonedoseincyclosporine-receiving
peritoneal dialysis (PD) versus haemodialysis (HD) has patients was 5590 mg compared with 3000 mg in tacrolimus-treated
significance for PTDM appearance. recipients.
Inaddition,thetacrolimus-treatedpatientsweresignificantlyyounger
than those taking cyclosporine (mean age, 42.3 ± 14.4 and 47.8 ±
11.4years,respectively,P=0.0029).
During the analysis period (12 months post-transplantation), steroid
Materials andmethods withdrawalwasnotattemptedbyanyofthepatients.
PTDM was diagnosed according to the current American Diabetic
Aretrospectivecohortof377consecutivepatientswhounderwentrenal Association (ADA)/World Health Organization (WHO) criteria.
transplantation in our institution between January 2003 and December ThecurrentADAcriteriafordiagnosisofdiabetesmellitusare:symp-
2005wereanalysed.Allgraftsweretransplantedfromdeceaseddonors. tomsofdiabetespluscasualplasmaglucoseconcentration≥200mg/dL
Three hundred and fifty patients received a first kidney graft, and 27 (11.1mmol/L),fastingplasmaglucose≥126mg/dL(7.0mmol/L),ora
receivedasecondtransplant.Duringthefirst12months,5patientschan- 2-h post-load glucose ≥200 mg/dL (11.1 mmol/L) during an oral glu-
gedtransplantcentre,12patientslostgraftfunctionand4patientsdied. cose tolerance test [12].
Table2. Clinicalcharacteristicsofpatientswithoutdiabetesmellitusat
Table1. Clinicalcharacteristicsofpatientswithoutdiabetesmellitusat
thedayoftransplantation(n=308)—qualitativeparameters
thedayoftransplantation(n=308)—quantitativeparameters
HD PD
Mann– Characteristic (n=260) (n=48) P-value
Whitney
HD PD U-test Genderofrecipient(F) 97(37.3%) 25(52%) 0.0545
Characteristic (n=260) (n=48) P-value Familyhistoryofdiabetesmellitus 58(22.3%) 11(22.9%) 0.9119
HCVinfectionattransplant 23(8.8%) 4(8.3%) 0.9081
Ageattransplant(years) 46.10±12.53 41.63±14.98 0.0554 Genderofdonor(F) 101(38.8%) 23(47.9%) 0.2391
Durationofdialysistherapy 30.15±29.41 19.40±14.82 0.0385* Primarydiagnosis
(months) Interstitialnephropathy 32(12.3%) 10(20.8%) 0.1138
BMIattransplant(kg/m2) 24.02±3.79 23.63±3.86 0.5569 Chronicglomerulardisease 134(51.5%) 20(41.7%) 0.2088
BMIat12months(kg/m2) 25.63±4.25 24.54±4.00 0.0493* Polycystickidneydisease 44(16.9%) 5(10.4%) 0.2575
ΔBMI(kg/m2) 1.61±2.45 0.91±2.74 0.0285* Hypertension 42(16.2%) 10(20.8%) 0.4265
CIT(hours) 24.53±6.97 23.26±7.22 0.2219 Other 8(3.1%) 3(6.3%) 0.2764
Cumulativemethylprednisolone 0.87±1.23 0.77±1.04 0.8600 Immunosuppressivetherapy
i.v.doseat12months(g) Cyclosporine 155(60.5%) 20(44.4%) 0.0211*
Donorage(years) 45.25±12.08 45.63±13.40 0.4788 Tacrolimus 101(39.5%) 25(55.6%) 0.0866
HLAmatches 2.45±0.82 2.52±0.95 0.5306 Azathioprine 122(46.9%) 13(27.1%) 0.0109*
HLAmismatches 3.55±0.82 3.48±0.95 0.5306 MMF 128(49.2%) 34(70.8%) 0.0059*
Rapamune 10(3.8%) 2(4.2%) 0.9160
Resultsaregivenasmean±SD.BMI,bodymassindex;CITcoldischae-
miatime. HCV,hepatitisCvirus;MMF,mycophenolatemofetil.
*P<0.05,statisticallysignificant. *P<0.05,statisticallysignificant.
Downloaded
from
http://ndt.oxfordjournals.org/
by
guest
on
November
13,
2015
1398 K.Madziarskaetal.
Table3. Comparisonofthequalitativeparametersbetweengroups(withPTDMversuswithoutPTDM)
PTDM(−) PTDM(+)
(n=236) (n=72)
Characteristic (%) (%) P-value Oddsratio
Genderofrecipient(F) 91(38.6) 31(43.1) 0.4947 1.205
Genderofdonor(F) 100(42.4) 24(33.3) 0.1710 0.680
Modalityofdialysis(PD) 31(13.1) 17(23.6) 0.0319* 2.044
Modalityofdialysis(HD) 205(86.9) 55(76.4) 0.0319 0.489
Familyhistoryofdiabetesmellitus 45(19.1) 24(33.3) 0.0046 2.366
HCVinfectionattransplant 20(8.5) 7(9.7) 0.7432 1.163
CMVinfectionat12months 37(15.7) 10(13.9) 0.7117 0.867
Herpesinfectionat12months 46(19.5) 17(23.6) 0.4481 1.277
Primarydiagnosis
Interstitialnephropathy 35(14.8) 7(9.7) 0.2689 0.618
Chronicglomerulardisease 125(53.0) 29(40.3) 0.0595 0.599
Polycystickidneydisease 35(14.8) 14(19.4) 0.3488 1.386
Hypertension 32(13.6) 20(27.8) 0.0048* 2.452
Other 9(3.8) 2(2.8) 0.6785 0.721
Immunosuppressivetherapy
Cyclosporine 135(57.2) 40(55.6) 0.8048 0.935
Tacrolimus 95(40.3) 31(43.1) 0.6722 1.122
Azathioprine 105(44.5) 30(41.7) 0.6724 0.891
MMF 120(50.8) 42(58.3) 0.2655 1.353
Rapamune 11(4.7) 1(1.4) 0.2091 0.288
HCV,hepatitisCvirus;CMV,cytomegalovirus;MMF,mycophenolatemofetil.
*P<0.05,statisticallysignificant.
Results PD (P = 0.0319, OR = 2.044 with 95% confidence
interval of 1.054–3.963).
Fromtheelementsoperatingaftertransplantationexclu-
Some disparities appeared between patients treated by
sively, older donor age was significantly associated with
HD and PD. Patients on maintenance PD were younger
PTDM(P=0.032,OR=1.023per1year).Theothercon-
(P = 0.0554), with higher percentage of females (P =
sidered factors, particularly the type of calcineurin inhibi-
0.0545) and shorter dialysis period (P = 0.0385). PD pa-
tor used,durationofcoldischaemiatime,numberofHLA
tients exhibited lesser weight gain during 12 months of
mismatches, cumulative methylprednisolone i.v. dose for
post-transplantation follow-up (P = 0.0285) and received
acute rejection treatment, gender of donor and recipient,
more frequently tacrolimus (P = 0.0866) and mycophe-
presence of hepatitis C virus (HCV) infection before
nolate mofetil (P = 0.0059) than cyclosporine and
RTx, cytomegalovirus (CMV) and herpes infections after
azathioprine. The average cumulative annual prednisone
RTx, and number of RTx (data not inserted), did not pre-
dose in PD group was 4150 mg versus 4570 mg in HD
dict PTDM development.
group.
In GLM analysis of covariance, the occurrence of
There was also difference in maintenance steroid dose
PTDM was significantly associated with the age of re- between cyclosporine- and tacrolimus-treated recipients
cipient (P < 0.001, OR = 1.051 per 1 year), family his-
(smaller in tacrolimus group).
tory of diabetes (P = 0.002, OR = 2.665), and PD
In the study group, 72 patients (23.4%) developed
treatment (P = 0.007, OR = 2.782) (Table 6). The lack
PTDM after RTx (55 HD and 17 PD patients). PTDM in-
of significant influence of other variables on PTDM risk
cidence at 3, 6 and 12 months was 15.9%, 22.1% and
could be the result of the relatively small number of pa-
23.4%, respectively. The mean interval from transplant-
tients for multivariate model. Referring to no discerned
ation to the onset of PTDM was 3.08 ± 2.73 months.
The comparison of the recipients with and without
PTDM is depicted in Tables 3–5. Table4. ModalityofdialysisversusPTDMwithconfidenceintervalat
The following factors not connected with transplant- the95%level
ation procedure and immunosuppressive regimen used,
alreadyexistingpriortotransplantation,exertedsignificant Confidence Confidence
PTDM(+) intervalfor Odds interval
impact on PTDM appearance: older recipient age (P <
Characteristic proportion proportion ratio forOR
0.001, OR = 1.050 per 1 year), positive family history of
diabetes (P = 0.0046, OR = 2.366), hypertensive nephro-
Modalityof 35.4% 21.3–49.5% 2.044 1.054–3.963
pathy versus glomerulonephritis, interstitial nephritis, dialysis(PD)
polycystic kidney disease and others as the end-stage n=48
renal disease (ESRD) cause (P = 0.0048, OR = 2.452), Modalityof 21.2% 15.8–26.6% 0.489 0.252–0.949
dialysis(HD)
higher body mass index (BMI) at transplantation day (P
n=260
= 0.045, OR = 1.066 per 1 kg/m2), and treatment by
Downloaded
from
http://ndt.oxfordjournals.org/
by
guest
on
November
13,
2015
TheincreasedriskofPTDMinPD-treatedkidneyrecipients 1399
Table 5. Comparison of the quantitative parameters between groups Itisofparticularnotethatthisassociationwasdisclosed
(withPTDMversuswithoutPTDM)andtheP-valuesofnon-parametric in multivariate analysis, albeit PD patients were younger
Mann–WhitneyU-testandoddsratiosfromsimplelogisticregression
(on the borderline of statistical significance, P = 0.055)
PTDM(−) PTDM(+) and exhibited significantly (P = 0.03) lower weight gain
Characteristic (n=236) (n=72) P-value OR post-transplantation (Table 1). Furthermore, the periods
of dialysis treatment were significantly shorter in PD
Ageattransplant 43.74±12.91 50.86±11.89 0.000* 1.050 group(P=0.04).Thepossibleconfoundingeffectofmore
(years) frequenttacrolimususeinthePDgroup(ontheborderline
Durationofdialysis 28.50±27.91 28.38±28.09 0.598 1.000 of significance P = 0.087) can be excluded based on the
(months)
fact that therewas no relationship between calcineurin in-
BMIattransplant 23.75±3.76 24.67±3.86 0.045* 1.066
(kg/m2) hibitor type and diabetes occurrence in the study group,
ΔBMI(kg) 1.69±2.52 0.87±2.34 0.006* 0.866 probably due toextensively smaller accompanying steroid
CIT(hours) 24.43±6.97 23.98±7.22 0.558 0.991 dose in the patients treated with tacrolimus (mean yearly
Cumulative 0.79±1.18 0.83±1.06 0.552 0.818
cumulative steroid dose in the tacrolimus group was
methylprednisolonei.v.
3000 mg versus 5590 mg in the cyclosporine patients).
doseat12months(g)
No.ofHLAmatches 2.44±0.84 2.53±0.86 0.806 1.125 In addition, the tacrolimus-treated patients were signifi-
No.ofHLAmismatches 3.56±0.84 3.47±0.86 0.806 0.889 cantly younger than those taking cyclosporine.
Donorage(years) 44.55±12.47 47.78±11.32 0.032* 1.023 Therefore, our data suggest that the glucose load asso-
ciated with PD therapy may increase the risk of PTDM
Resultsaregivenasmean±SD.BMI,bodymassindex;CIT,coldischae-
development. Recently, Bergrem et al. reported that pre- miatime.
*P<0.05,statisticallysignificant. transplant impaired glucose tolerance, revealed by a
standard oral glucose tolerance test, was predictive for
hyperglycaemia appearance 10 weeks post-transplant.
However, they did not consider in the investigation the
differences between the kinds of calcineurin inhibitor
effect of dialysis modality. The major factor underlying
used, it should be underlined that the tacrolimus-treated PTDM occurrence in their study population was the re-
patients were significantly younger than those taking
cipient agewhich was previously reported [13]. The men-
cyclosporine.
tion of PD treatment appears in the latest paper published
Influence of PD on risk of PTDM is even higher in
by Hornum et al. after this manuscript submission [14].
multivariate model because PD patients are younger than
In a smaller group of 57 kidneytransplant recipients from
HD patients. The difference in risk of PTDM develop-
live donors, they did not observe the impact of positive
ment between PD- and HD-treated patients is depicted
family history of diabetes and PD as treatment modality
in Figure 1 and with respect to the age factor in Figure 2.
on PTDM occurrence.
Consideringtheageofrecipients,theprobabilityofPTDM
Noteworthy,accordingtoourdata,theriskofPTDMin
appearance was below the age 50 years in PD patients,
PD patients below age 50 years was similar to the risk in
similar to the rate of occurrence in HD group older than
HD patients above50 years,with starting point of risk in-
50 years.
crease at age 40 years.
The remaining elements, i.e. hypertensive nephropathy,
higher BMI and older donor age, were strongly correlated
Discussion
with the age of recipients. In fact, it reflects the more
frequent occurrence of hypertensive nephropathy and
In the cohort of kidney transplant recipients under this
BMI increase in older recipients, and the higher prob-
study,theappearanceofPTDMwasalmostexclusivelyaf-
ability to receive allograft from older donor. The lack
fectedbypatientpre-transplantclinicalcharacteristics.The
of difference in PTDM frequency between cyclosporine-
factors significantly augmenting PTDM occurrence were
andtacrolimus-treatedpatientsseemstobecausedbyhigher
older recipient age (P ≤ 0.001), hypertensivenephropathy
as the ESRD cause (P ≤ 0.01), higher BMI at transplant-
ation day (P ≤ 0.05), and PD as the method of renal re-
placement therapy (P ≤ 0.05 versus HD). The only
Table6. GLMofanalysisofcovariance(influencebothqualitativeand
factor associated with transplant procedure significantly
quantitativevariablesonPTDM)
contributing to PTDM development was older donor age
(P ≤ 0.05). The multivariate analysis revealed that the in-
PTDM0/1logitlinkfunction
dependent significant predictors of PTDM development
Effect Estimate OR Waldstatistics P
were recipient age, positive family history of diabetes,
and PD treatment. The novel finding, not reported in pre-
Intercept 3.059 21.184 0.000
vious literature, is the observation of significantly higher
Recipientageat 0.050 1.051 13.392 0.000
rate of PTDM in the PD-treated patients compared with transplant(year)
the number in HD group. The proportion of PD patients Modalityofdialysis 0.512 2.782 7.365 0.007
with PTDM was 35.4% with 95% confidence interval of treatment:PD/HD
21.3–49.5%versustheproportionofHDpatientsequalto Familyhistoryof 0.490 2.665 9.165 0.002
21.2% with 95% confidence interval of 15.8–26.6%. diabetesmellitus
Downloaded
from
http://ndt.oxfordjournals.org/
by
guest
on
November
13,
2015
1400 K.Madziarskaetal.
Fig.1. Kaplan–Meiersurvivalfunction.ThedifferenceinriskofPTDMdevelopmentwithrespecttomodalityofdialysistreatment—PDversusHD.
accompanyingprednisonedosesinourcyclosporine-based transplantation,treatmentbyPD,andthegraftfromanold-
immunosuppressiveregimen. er donor. The recipients carrying these features should
Insummary,thepresentstudyhasidentifiedthefeatures undergodetailedpre-transplantglucosemetabolismevalu-
oftherecipientsassociatedwithanelevatedriskofPTDM ationwithoraltestforglucoseintolerance, andbeconsid-
development,suchasolderage,familyhistoryofdiabetes, ered for calcineurin inhibitors or steroid-minimization
hypertensive nephropathy as ESRD cause, higher BMI at protocols.
Fig.2. Kaplan–Meiersurvivalfunction.ThedifferenceinriskofPTDMdevelopmentwithrespecttotheagefactor.
Downloaded
from
http://ndt.oxfordjournals.org/
by
guest
on
November
13,
2015
HIVinfectionandrenaltransplantation 1401
Itisofnotethat49casesofPTDMfromthetotalnum- 5. RevanurVK,JardineAG,KingsmoreDBetal.Influenceofdiabetes
ber of 72 cases during 1 year were developed during the mellituson patient and graft survivalinrecipientsofkidneytrans-
first 3 months post-transplantation.
plantation.ClinTransplant2001;15:89–94
6. Cosio FG, Pesavento TE, Kim S et al. Patient survival after renal
transplantation: IV. Impact of post-transplant diabetes. Kidney Int
2002;62:1440–1446
Conclusions 7. HagenM,HjelmesaethJ,JenssenTetal.A6-yearprospectivestudy
onnewonsetdiabetesmellitus,insulinreleaseandinsulinsensitivity
in renal transplant recipients. Nephrol Dial Transplant 2003; 18:
InevaluatingtheriskofPTDMoccurrence,moreattention 2154–2159
shouldbe paid to thestratification ofthepredisposingab-
8. Gentil MA, Luna E, Rodriguez-Algarra G et al. Incidence of dia-
normalities present during the dialysis period. Treatment betesmellitus requiring insulin treatmentafter renal transplantation
by PD may increase the risk of PTDM development. in patients with hepatitis C. Nephrol Dial Transplant 2002; 17:
887–891
9. DuclouxD,KazoryA,ChalopinJ-M.Posttransplantdiabetesmelli-
Conflictofintereststatement.Nonedeclared. tus and atherosclerotic events in renal transplant recipients: a pro-
spectivestudy.Transplantation2005;79:438–443
10. SulancE,LaneJT,PuumalaSEetal.New-onsetdiabetesafterkid-
References neytransplantation:anapplicationof2003internationalguidelines.
Transplantation2005;80:945–952
1. Kasiske BL, Snyder JJ, Gilbertson D et al. Diabetes mellitus after 11. SatoT,InagakiA,UchidaKetal.Diabetesmellitusaftertransplant:
kidneytransplantation intheUnitedStates. AmJTransplant2003; relationship to pretransplant glucose metabolism and tacrolimusor
3:178–185 cyclosporineA-basedtherapy.Transplantation2003;76:1320–1326
2. Woodward RS, Schnitzler MA, Baty Jet al.Incidence and costof 12. AmericanDiabetesAssociation.Diagnosisandclassificationofdia-
newonsetdiabetesmellitusamongU.S.wait-listedandtransplanted betesmellitus.DiabCare2004;27:S5–S10
renalallograftrecipients.AmJTransplant2003;3:590–598 13. BergremHA,ValderhaugTG,HartmannAetal.Glucosetolerance
3. Davidson J, Wilkinson A, Dantal Jet al. New-onset diabetes after beforeandafter.NephrolDialTransplant2010;25:985–992
transplantation:2003internationalconsensusguidelines.Transplant- 14. Hornum M, Jørgensen KA, Hansen JM et al. New-onset diabetes
ation2003;75:SS3–SS24 mellitus after kidney transplantation in Denmark. Clin J Am Soc
4. Gourishankar S, Jhangri GS,Tonelli Metal.Developmentofdia- Nephrol 2010; 5: 709–716
betes mellitus followingkidneytransplantation: aCanadianexperi-
ence.AmJTransplant2004;4:1876–1882 Receivedforpublication:23.2.10;Acceptedinrevisedform:25.8.10
NephrolDialTransplant(2011)26:1401–1407
doi:10.1093/ndt/gfq592
AdvanceAccesspublication21September2010
HIV infection and renal transplantation
Auxiliadora Mazuecos1, Ana Fernandez2, Amado Andres3, Ernesto Gomez4, Sofia Zarraga5,
Dolores Burgos6,CarlosJimenez7,Javier Paul8,AlbertoRodriguez-Benot9andConstantino Fernandez10
1Department of Nephrology,Hospital Puertadel Mar,Cadiz, Spain,2Departmentof Nephrology,Hospital Ramony Cajal,Madrid,
Spain, 3Departmentof Nephrology,Hospital Doce deOctubre,Madrid,Spain, 4Department of Nephrology,Hospital deAsturias,
Oviedo,Spain,5DepartmentofNephrology,HospitaldeCruces,Barakaldo,Spain,6DepartmentofNephrology,HospitalCarlosHaya,
Malaga, Spain,7Departmentof Nephrology,Hospital LaPaz,Madrid, Spain,8Departmentof Nephrology,Hospital Miguel Servet,
Zaragoza,Spain,9DepartmentofNephrology,HospitalReinaSofia,Cordoba,Spainand10DepartmentofNephrology,HospitalJuan
Canalejo, ACoruña,Spain
Correspondence andoffprint requests to: AuxiliadoraMazuecos;E-mail: mauxiliadora.mazuecos.sspa@juntadeandalucia.es
Abstract tientsinSpain.TwentyHIV+patientswerecomparedwith
Background. Some aspects of kidney transplant outcome a matched cohort of 40 HIV− recipients.
inhumanimmunodeficiencyvirus(HIV)-infectedpatients Results. Post-transplant follow-up period was 39.98 ±
are still controversial. Besides, published experience is 36.51 months. Pre-transplant dialysis duration and the in-
scarce in Europe. cidence of pre-transplant opportunistic infections were
Methods. A multicentre case–control study was designed significantly higher for HIV+ patients. Following trans-
to analyse the outcome of renal transplant in HIV+ pa- plantation, HIV+ recipients presented lower incidence of
©TheAuthor2010.PublishedbyOxfordUniversityPressonbehalfofERA-EDTA.Allrightsreserved.
ForPermissions,pleasee-mail:journals.permissions@oxfordjournals.org
Downloaded
from
http://ndt.oxfordjournals.org/
by
guest
on
November
13,
2015
